PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for ...

Slower visual field loss in patients with primary open-angle glaucoma was linked to greater physical activity, suggesting ...

Diorasis Therapeutics has partnered with Northway Biotech to establish a scalable cGMP production process for DTx’s lead ...

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and ...

Disc hemorrhage location was associated with areas of clustered visual field progression in patients with primary open-angle ...

Filtration surgery effectively lowers IOP and slows central visual field deterioration in open-angle glaucoma and high myopia.

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma ...

Diorasis Therapeutics & Northway Biotech partner to develop and manufacture AAV gene therapy for glaucoma: Boston, Massachusetts Thursday, July 31, 2025, 16:00 Hrs [IST] Diorasis ...

Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has ...

Approximately half of all childhood glaucoma surgeries in the United States fail within the first year, according to AAO data.

A new study suggests that a specific combination of vitamins may help slow down damage to the optic nerve in people with ...